|
 |
    |
SelectX's
platforms (see the Science & Technology page
for details) are broadly applicable for drug discovery and development of virtually
all classes of therapeutics, permitting opportunities for
collaborative initiatives as well as in-house proprietary product
development.
Preclinical PipelineUsing Directed Discovery™ and ComGene™, and fully-integrated related technologies such as bioinformatics and genomics, a preclinical pipeline is rapidly being generated and characterized from proprietary, chemotype-focused small molecule libraries. Currently, novel compounds include aminoglycosides, polyketides, lactams, glycosides, terpenes, and antimetabolites. These chemotypes broadly span the therapeutic focus areas of the Company's in-house program. The diversity and molecular complexity of these libraries is exemplified by single compounds that contain two or more of these chemotypes, illustrating the unmatched diverse biofunctionality provided by these platforms. Although many novel compounds are too complex to synthesize using conventional chemical synthesis, both Directed Discovery™ and ComGene™ are quantitatively scalable. Antibiotic Resistance PredictionDART™ is being used to predict and characterize the molecular and physiological mechanisms of antibiotic resistance prior to clinical emergence. This also provides novel, validated drug resistance intervention targets. Case studies of the successful application of DART™ include 100% accurate prediction of resistance to extended spectrum b-lactams (including inhibitor resistant forms) and quinolones. The b-lactam study was conducted in cooperation with Glaxo and Fermic. Importantly, novel mechanisms of resistance have also been discovered and predicted to emerge. These resistant mutants, representative of future clinical resistance, are being used for the development of next-generation antibiotics effective against these emerging pathogens. |
